drugset / Trial / NCT03466294

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

NCT03466294 ↗

Phase 2 Completed 42 enrolled University of Colorado, Denver
NaSingle-groupOpen-labelTreatment

Summary

This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment. Azacitidine and venetoclax will be given as induction treatment followed by venetoclax maintenance treatment for patients who respond to the induction treatment.

Timeline

Start
2018-05-15
Primary completion
2025-01-29
Completion
2025-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Other
Subject Venetoclax Small molecule 600 mg Oral